Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 12/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673058 | 1.00 | TYMP (0.87) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL9548719 | 0.89 | TYMP (0.82) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL29441277 | 0.88 | TYMP (0.68) | TYMPPOLBTYMSGSK3ARPS6KA3 | |
| SCHEMBL10623534 | 0.88 | TYMP (0.68) | TYMPPOLBTYMSGSK3ARPS6KA3 | |
| SCHEMBL30274736 | 0.87 | TYMP (0.66) | TYMPTYMS | |
| SCHEMBL30274783 | 0.87 | TYMP (0.66) | TYMPTYMS | |
| SCHEMBL7871248 | 0.85 | TYMP (0.63) | TYMPPOLB | |
| SCHEMBL20691415 | 0.85 | TYMP (1.00) | TYMPGSK3ARPS6KA3MAPK14P2RX3 | |
| SCHEMBL1774838 | 0.85 | TYMP (0.63) | TYMPPOLB | |
| SCHEMBL29529385 | 0.85 | TYMP (0.63) | TYMPPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025047679-A1 | STABLE TARGET EDITING GUIDE RNA HAVING PHOSPHATE MOIETY MODIFICATION INTRODUCED THEREINTO | 学校法人福岡大学 | 2025-03-06 | — | — | WO | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| EP-4022059-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | Wave Life Sciences Ltd. (SG) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021071858-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| EP-3130597-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | Kyowa Hakko Kirin Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | TYMP 120/4885ALDH1A1 2042/4885LMNA 778/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | TYMP 121/4885ALDH1A1 2066/4885LMNA 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.